Spectral karyotyping is a way to look at all the chromosomes in a cell. It uses special fluorescent labels to identify each chromosome and see how they look. This helps doctors understand genetic conditions.
Every report comes from a Lived member, sent anonymously.
No reports yet
Add what worked for you with the search bar below
Spectral karyotyping (SKY) is a laboratory test that paints each of the 24 different human chromosomes (chromosomes 1 through 22, plus X and Y) in its own color. Chromosomes are the structures that package a cell's DNA. Fluorescent DNA probes attach to each chromosome and an imaging system reads the light they give off, so a piece of one chromosome that has broken off and joined another shows up as a patch of a different color. SKY is rarely the first chromosome test. It is usually added after a standard karyotype, the routine microscope analysis of chromosomes, has found something it cannot fully identify: a small extra chromosome (called a marker chromosome) or material that has moved between chromosomes. Such findings can come up when a child has developmental delay or several birth differences, during an infertility evaluation, after an amniocentesis in pregnancy, or in the bone marrow cells of someone with leukemia, where complex chromosome rearrangements are common. Knowing where the extra or rearranged material came from helps a genetics team judge what it may mean, and can show whether a parent carries a balanced rearrangement (one where no genetic material is gained or lost) that could matter for future pregnancies. Chromosomal microarray, a test that measures small gains and losses of DNA, has increasingly taken over many of these jobs. SKY remains useful when chromosomes need to be seen as whole structures, for example to find balanced rearrangements, which a microarray cannot detect, to sort out a very complex set of changes, or to look for a change present in only some of a person's cells.
Because SKY is done on a sample in the laboratory, preparation depends on how that sample is collected. For a blood sample there is usually nothing special to do. If the sample comes from a bone marrow biopsy, or from amniocentesis or placental sampling during pregnancy, the care team gives separate instructions for that procedure. It helps to understand the purpose of the test before it is done. A genetic counselor or geneticist can explain what earlier result led to SKY, what kinds of answers it can and cannot give, and whether samples from parents or other relatives may also be requested to interpret the findings.
For the person being tested, the experience is the sample collection. Most often that is an ordinary blood draw from a vein in the arm. For leukemia and some other blood disorders, the sample usually comes from a bone marrow biopsy. During pregnancy, cells come from amniotic fluid collected by amniocentesis or from a small sample of the placenta. Each of these collection methods has its own steps and level of discomfort, which the care team describes beforehand. The rest happens in the laboratory. Cells from the sample are grown until they divide, the stage at which chromosomes can be photographed as separate shapes. Fluorescent probes are then applied, and a spectral imaging system assigns each chromosome its color. A cytogeneticist, a specialist in chromosome analysis, compares the colored images with the standard banded karyotype to work out which chromosomes are involved.
Recovery is recovery from the sample collection. After a blood draw, people return to their usual activities right away. A bone marrow biopsy or amniocentesis has its own aftercare, which the team explains. Results take longer than a routine blood test because the cells must first grow in the lab, and timing varies between laboratories. A SKY result is usually not the final step. The finding is typically confirmed with FISH (fluorescence in situ hybridization), a test that uses probes aimed at one specific chromosome region, or by testing the parents, and a microarray may be added to measure how much genetic material is involved. A genetic counselor or geneticist then explains what the combined results suggest for health, development or future pregnancies. When SKY is part of a leukemia evaluation, it describes changes that arose in the cancer cells, not inherited ones, and the results help the hematology team characterize the disease.
The analysis itself carries no physical risk beyond collecting the sample. A blood draw is minor. Bone marrow biopsy and prenatal sampling are more involved procedures with their own risks, which are worth discussing before they are done. The more important limits concern what SKY can see. Because each chromosome is a single color, a change inside one chromosome, such as a missing, duplicated or flipped segment, can look normal. Pieces smaller than roughly 1 to 2 million DNA base pairs can be missed. SKY can show which chromosome extra material came from, but not exactly how large it is or which genes it contains, so on its own it cannot predict how a finding will affect health or development. In one large reference laboratory series, SKY identified the origin of the unidentified material in about 88% of cases; it mainly failed when the change was present in very few cells or contained very little genetic material. Cells grown in the lab occasionally develop problems that do not reflect the body, so abnormal results are confirmed before decisions rest on them. In pregnancy in particular, SKY is not considered reliable enough to be used alone for diagnosis, and its results are checked with other tests.
Last reviewed • Oct 2026
Educational content, not medical advice.
Share your experience with Spectral Karyotyping, what to expect, or ask the community a question.